Nektar Therapeutics

NASDAQ:NKTR

Biotechnology

Healthcare
$34.42 -2.04%

-$1.24 today

Market cap
$987.44M
Beta
1.15
P/E (TTM)
-9.3
EPS (TTM)
-$6.39
52W Low $8.27High $109.00

Volume 0.71M

Average 1.00M

NKTR Interest Income

Income earned on cash, deposits, and investments held by the company.

Nektar TherapeuticsNASDAQ: NKTR

Interest Income · Q2 FY2026 · quarter ended Jun 2026

Interest income growth accelerates

Q2 FY2026 interest income of $9.35M rose 374.7% year over year, ahead of the +70.9% change in trailing-twelve-month interest income. Sequentially, it rose 120.3% from the prior quarter. Over 3 fiscal years it compounded at +15.5% a year.

Context

  • Interest income amounted to 18.9% of revenue in FY2025, up 4.2 pp from a year earlier.
  • Interest income increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +374.7% holds above the trailing-twelve-month pace of +70.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$9.35M+120.3% QoQ
Last fiscal yearDec 2025
$10.44M-28.0% YoY
LTMJun 2026
$19.18M+70.9% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+374.7%——
1 year-28.0%——
3-year CAGR+15.5%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
10.44M USD
Year-over-year change
-28.0%
4-year CAGR
+39.8%

Interest Income vs competitors

How NKTR compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +70.9% is the highest of 9, against a peer median of -33.6%.
  • Interest income amounts to 35.1% of revenue for NKTR, versus a peer median of 21.9%.
NKTR Competitors
Interest Income for NKTR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCUSArcus Biosciences, Inc.LTM Jun 2026$58M USD+23.4%+36.8%49.6%
XNCRXencor, Inc.LTM Jun 2026$23M USD-24.6%+78.8%21.9%
NKTRNektar TherapeuticsLTM Jun 2026$19.18M USD+70.9%+15.5%35.1%
IMTXImmatics N.V.LTM Mar 2026€15.3M EUR-36.7%+90.7%41.0%
IMCRImmunocore Holdings plcLTM Mar 2026$14.94M USD-30.5%+63.7%3.9%
MGNXMacroGenics, Inc.LTM Mar 2026$5.93M USD-29.4%+26.0%3.8%
CGENCompugen Ltd.LTM Mar 2026$2.66M USD-49.0%+45.3%3.7%
ANLAdlai Nortye Ltd.LTM Jun 2024$1.49M USD—-87.8%23.0%
IPHAInnate Pharma S.A.FY2025€1.32M EUR-45.9%+34.1%47.3%
CHRSCoherus Oncology, Inc.LTM Mar 2026$0 USD——0.0%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$525K USD-125.8%+56.5%—
Peer median (excluding NKTR) —-33.6%+45.3%21.9%

Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue101.91M92.06M90.12M98.43M55.23M
Cost of Revenue24.9M21.64M36.64M30.69M0
Gross Profit77.01M70.42M53.48M67.74M55.23M
Gross Margin75.6%76.5%59.3%68.8%100.0%
Research & Development400.27M218.32M114.16M120.91M117.33M
Selling, General & Admin122.84M92.33M77.42M76.75M68.67M
Operating Expenses523.11M310.66M190.9M172.94M186M
Depreciation & Amortization14.15M12.2M7.82M4.39M1.03M
EBITDA(461.82M)(323.87M)(243.11M)(86.7M)(137M)
EBITDA Margin-453.2%-351.8%-269.8%-88.1%-248.1%
Operating Income(446.1M)(240.24M)(137.43M)(105.2M)(130.77M)
Operating Margin-437.8%-261.0%-152.5%-106.9%-236.8%
Interest Income2.73M6.78M19.01M14.5M10.44M
Interest Expense47.31M28.91M25.33M28.11M26.18M
Other Income / Expenses(77.18M)(124.75M)(138.83M)(14M)(33.44M)
Income Before Tax(523.28M)(364.98M)(276.26M)(119.2M)(164.21M)
Pre-Tax Margin-513.5%-396.5%-306.5%-121.1%-297.3%
Income Tax Expense557K3.22M(200K)(239K)(138K)
Net Income(523.84M)(368.2M)(276.06M)(118.96M)(164.08M)
Net Margin-514.0%-400.0%-306.3%-120.9%-297.1%
EPS (Basic)(42.90)(29.51)(21.79)(8.68)(9.73)
EPS (Diluted)(42.90)(29.51)(21.79)(8.68)(9.73)
Weighted Avg Shares12.22M12.48M12.67M13.71M16.87M
Weighted Avg Shares (Diluted)12.22M12.48M12.67M13.71M16.87M

Nektar Therapeutics

NASDAQ:NKTR

Intrinsic Alpha fair value

Locked

Current Price

$34.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.